β3-adrenoceptor activation relieves oxidative inhibition of the cardiac na+-k+ pump in hyperglycemia induced by insulin receptor blockade

American Journal of Physiology - Cell Physiology

Volumn 309, Issue 5, 2015, Pages C286-C295

  Galougahi, Keyvan Karimi ^a,b   Liu, Chia Chi ^a   Garcia, Alvaro ^a   Fry, Natasha A ^a   Hamilton, Elisha J ^a   Figtree, Gemma A ^a,b   Rasmussen, Helge H ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Diabetes; Endothelial nitric oxide synthase; Glutathionylation; Hyperglycemia; Na+ K+ pump; 3 adrenergic receptors

Indexed keywords

5 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,3 BENZODIOXOLE 2,2 DICARBOXYLIC ACID; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ARGININE; BETA 3 ADRENERGIC RECEPTOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; GLUTAREDOXIN; GLUTAREDOXIN 1; INSULIN; INSULIN RECEPTOR; OUABAIN; PROTEIN P22; PROTEIN P47; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; UNCLASSIFIED DRUG; 1,3 DIOXOLANE DERIVATIVE; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; DISODIUM (R,R)-5-(2-((2-(3-CHLOROPHENYL)-2-HYDROXYETHYL)-AMINO)PROPYL)-1,3-BENZODIOXOLE-2,3-DICARBOXYLATE; GLUCOSE BLOOD LEVEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVATION; EX VIVO STUDY; GLUCOSE BLOOD LEVEL; HEART MUSCLE CELL; HYPERGLYCEMIA; IMMUNOPRECIPITATION; IN VIVO STUDY; INSULIN BLOOD LEVEL; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RABBIT; RECEPTOR BLOCKING; TURNOVER TIME; VOLTAGE CLAMP TECHNIQUE; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; MOLECULAR GENETICS; PHYSIOLOGY;

ADRENERGIC BETA-3 RECEPTOR AGONISTS; AMINO ACID SEQUENCE; ANIMALS; BLOOD GLUCOSE; DIOXOLES; HYPERGLYCEMIA; MALE; MOLECULAR SEQUENCE DATA; OXIDATIVE STRESS; RABBITS; RECEPTOR, INSULIN; RECEPTORS, ADRENERGIC, BETA-3; SODIUM-POTASSIUM-EXCHANGING ATPASE;

EID: 84940747132     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00071.2015     Document Type: Article

References (53)

1. Aistrup GL, Balke CW, Wasserstrom JA. Arrhythmia triggers in heart failure: the smoking gun of [Ca2+]i dysregulation. Heart Rhythm 8: 1804-1808, 2011.
2. Altan VM, Arioglu E, Guner S, Ozcelikay AT. The influence of diabetes on cardiac β-adrenoceptor subtypes. Heart Fail Rev 12: 58-65, 2007.
3. Audigane L, Kerfant BG, El Harchi A, Lorenzen-Schmidt I, Toumaniantz G, Cantereau A, Potreau D, Charpentier F, Noireaud J, Gauthier C. Rabbit, a relevant model for the study of cardiac β3-adrenoceptors. Exp Physiol 94: 400-411, 2009.
4. Bakopanos E, Silva JE. Thiazolidinediones inhibit the expression of β3-adrenergic receptors at a transcriptional level. Diabetes 49: 2108-2115, 2000.
5. Bay J, Kohlhaas M, Maack C. Intracellular Na+ and cardiac metabolism. J Mol Cell Cardiol 61: 20-27, 2013.
6. Belge C, Hammond J, Dubois-Deruy E, Manoury B, Hamelet J, Beauloye C, Markl A, Pouleur AC, Bertrand L, Esfahani H, Jnaoui K, Gotz KR, Nikolaev VO, Vanderper A, Herijgers P, Lobysheva I, Iaccarino G, Hilfiker-Kleiner D, Tavernier G, Langin D, Dessy C, Balligand JL. Enhanced expression of β3-adrenoceptors in cardiac myocytes attenuates neurohormone-induced hypertrophic remodeling through nitric oxide synthase. Circulation 129: 451-462, 2014.
7. Bibert S, Liu CC, Figtree GA, Garcia A, Hamilton EJ, Marassi FM, Sweadner KJ, Cornelius F, Geering K, Rasmussen HH. FXYD proteins reverse inhibition of the Na+-K+ pump mediated by glutathionylation of its β1 subunit. J Biol Chem 286: 18562-18572, 2011.
8. Black SM. 3-Adrenoceptor, glutathionylation, and diabetic cardiomyopathy. Focus on “β3-Adrenoceptor activation relieves oxidative inhibition of the cardiac Na+-K+ pump in hyperglycemia induced by insulin receptor blockade.” Am J Physiol Cell Physiol (July 15, 2015). doi:10.1152/ajpcell.00196.2015.
9. Boudina S, Abel ED. Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord 11: 31-39, 2010.
10. Bundgaard H, Liu CC, Garcia A, Hamilton EJ, Huang Y, Chia KK, Hunyor SN, Figtree GA, Rasmussen HH. β3-Adrenergic stimulation of the cardiac Na+-K+ pump by reversal of an inhibitory oxidative modification. Circulation 122: 2699-2708, 2010.
11. Chen CA, Wang TY, Varadharaj S, Reyes LA, Hemann C, Talukder MA, Chen YR, Druhan LJ, Zweier JL. S-glutathionylation uncouples eNOS and regulates its cellular and vascular function. Nature 468: 1115-1118, 2010.
12. Chia KK, Liu CC, Hamilton EJ, Garcia A, Fry NA, Hannam W, Figtree GA, Rasmussen HH. Stimulation of the cardiac myocyte Na+-K+ pump due to reversal of its constitutive oxidation inhibition. Am J Physiol Cell Physiol (June 17, 2015). doi:10.1152/ajpcell.00392.2014.
13. National Library of Medicine. β3-Agonist treatment in heart failure (Online). http://clinicaltrials.gov/show/NCT01876433 [17 July 2015]
14. Figtree GA, Liu CC, Bibert S, Hamilton EJ, Garcia A, White CN, Chia KK, Cornelius F, Geering K, Rasmussen HH. Reversible oxidative modification: A key mechanism of Na+-K+ pump regulation. Circ Res 105: 185-193, 2009.
15. Fry NA, Garcia A, Karimi Galougahi K, Liu CC, Hamilton EJ, McLachlan CS, Figtree GA, Rasmussen HH. Treatment with β3-adrenergic receptor agonist in heart failure reverses an oxidative modification and inhibition of the Na+-K+ pump in cardiac myocytes and improves pulmonary congestion (Abstract). Circulation 128: A17142, 2012.
16. Gallogly MM, Mieyal JJ. Mechanisms of reversible protein glutathionylation in redox signaling and oxidative stress. Curr Opin Pharmacol 7: 381-391, 2007.
17. Gallogly MM, Starke DW, Mieyal JJ. Mechanistic and kinetic details of catalysis of thiol-disulfide exchange by glutaredoxins and potential mechanisms of regulation. Antioxid Redox Signal 11: 1059-1081, 2009.
18. Galougahi KK, Liu CC, Bundgaard H, Rasmussen HH. β-Adrenergic regulation of the cardiac Na+-K+ ATPase mediated by oxidative signaling. Trends Cardiovasc Med 22: 83-87, 2012.
19. Galougahi KK, Liu CC, Fry NA, Garcia A, Hawkins CL, Rasmussen HH, Figtree GA. β3-Adrenergic stimulation protects against eNOS uncoupling, oxidative Na+-K+ pump inhibition and vascular dysfunction in type 2 diabetes (Abstract). Circulation 126: A16278, 2012.
20. Galougahi KK, Liu CC, Garcia A, Fry NA, Hamilton EJ, Rasmussen HH, Figtree GA. Protein kinase-dependent oxidative regulation of the cardiac Na+-K+ pump: evidence from in vivo and in vitro modulation of cell signalling. J Physiol 591: 2999-3015, 2013.
21. Gao L, Mann GE. Vascular NAD(P)H oxidase activation in diabetes: a double-edged sword in redox signalling. Cardiovasc Res 82: 9-20, 2009.
22. Guzik TJ, Harrison DG. Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discov Today 11: 524-533, 2006.
23. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, Channon KM. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 105: 1656-1662, 2002.
24. Han G, Ma H, Chintala R, Fulton DJ, Barman SA, White RE. Essential role of the 90-kilodalton heat shock protein in mediating nongenomic estrogen signaling in coronary artery smooth muscle. J Pharmacol Exp Ther 329: 850-855, 2009.
25. Hansen PS, Clarke RJ, Buhagiar KA, Hamilton E, Garcia A, White C, Rasmussen HH. Alloxan-induced diabetes reduces sarcolemmal Na+-K+ pump function in rabbit ventricular myocytes. Am J Physiol Cell Physiol 292: C1070-C1077, 2007.
26. Hool LC, Whalley DW, Doohan MM, Rasmussen HH. Angiotensinconverting enzyme inhibition, intracellular Na+, and Na+-K+ pumping in cardiac myocytes. Am J Physiol Cell Physiol 268: C366-C375, 1995.
27. King AJ. The use of animal models in diabetes research. Br J Pharmacol 166: 877-894, 2012.
28. Komajda M, McMurray JJ, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, Curtis PS, Jones NP, Home PD. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J 31: 824-831, 2010.
29. Lassegue B, San Martin A, Griendling KK. Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system. Circ Res 110: 1364-1390, 2012.
30. Liu CC, Fry NA, Hamilton EJ, Chia KK, Garcia A, Karimi Galougahi K, Figtree GA, Clarke RJ, Bundgaard H, Rasmussen HH. Redoxdependent regulation of the Na+-K+ pump: new twists to an old target for treatment of heart failure. J Mol Cell Cardiol 61: 94-101, 2013.
31. Moens AL, Leyton-Mange JS, Niu X, Yang R, Cingolani O, Arkenbout EK, Champion HC, Bedja D, Gabrielson KL, Chen J, Xia Y, Hale AB, Channon KM, Halushka MK, Barker N, Wuyts FL, Kaminski PM, Wolin MS, Kass DA, Barouch LA. Adverse ventricular remodeling and exacerbated NOS uncoupling from pressure-overload in mice lacking the β3-adrenoreceptor. J Mol Cell Cardiol 47: 576-585, 2009.
32. Moens AL, Yang R, Watts VL, Barouch LA. β3-Adrenoreceptor regulation of nitric oxide in the cardiovascular system. J Mol Cell Cardiol 48: 1088-1095, 2010.
33. Moniotte S, Kobzik L, Feron O, Trochu JN, Gauthier C, Balligand JL. Upregulation of β3-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. Circulation 103: 1649-1655, 2001.
34. Niu X, Watts VL, Cingolani OH, Sivakumaran V, Leyton-Mange JS, Ellis CL, Miller KL, Vandegaer K, Bedja D, Gabrielson KL, Paolocci N, Kass DA, Barouch LA. Cardioprotective effect of β3-adrenergic receptor agonism: role of neuronal nitric oxide synthase. J Am Coll Cardiol 59: 1979-1987, 2012.
35. Peltoniemi MJ, Karala AR, Jurvansuu JK, Kinnula VL, Ruddock LW. Insights into deglutathionylation reactions. Different intermediates in the glutaredoxin and protein disulfide isomerase catalyzed reactions are defined by the linkage present in glutathione. J Biol Chem 281: 33107-33114, 2006.
36. Pieske B, Houser SR. [Na+]i handling in the failing human heart. Cardiovasc Res 57: 874-886, 2003.
37. Pogwizd SM, Sipido KR, Verdonck F, Bers DM. Intracellular Na in animal models of hypertrophy and heart failure: contractile function and arrhythmogenesis. Cardiovasc Res 57: 887-896, 2003.
38. Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res 98: 596-605, 2006.
39. Rasmussen HH, Figtree GA, Krum H, Bundgaard H. Treatment of heart failure with β3-receptor agonists. Curr Opin Invest Drugs 10: 955-962, 2009.
40. Sakurai K, Katoh M, Fujimoto Y. Alloxan-induced mitochondrial permeability transition triggered by calcium, thiol oxidation, and matrix ATP. J Biol Chem 276: 26942-26946, 2001.
41. Sam S, Haffner S, Davidson MH, D’Agostino RB, Feinstein S, Kondos G, Perez A, Mazzone T. Relation of abdominal fat depots to systemic markers of inflammation in type 2 diabetes. Diabetes Care 32: 932-937, 2009.
42. Schaffer L, Brand CL, Hansen BF, Ribel U, Shaw AC, Slaaby R, Sturis J. A novel high-affinity peptide antagonist to the insulin receptor. Biochem Biophys Res Commun 376: 380-383, 2008.
43. Schuhmacher S, Oelze M, Bollmann F, Kleinert H, Otto C, Heeren T, Steven S, Hausding M, Knorr M, Pautz A, Reifenberg K, Schulz E, Gori T, Wenzel P, Munzel T, Daiber A. Vascular dysfunction in experimental diabetes is improved by pentaerithrityl tetranitrate but not isosorbide-5-mononitrate therapy. Diabetes 60: 2608-2616, 2011.
44. Shi Y, Baker JE, Zhang C, Tweddell JS, Su J, Pritchard KA. Chronic hypoxia increases endothelial nitric oxide synthase generation of nitric oxide by increasing heat shock protein 90 association and serine phosphorylation. Circ Res 91: 300-306, 2002.
45. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298: 1189-1195, 2007.
46. Trevisan M, Browne R, Ram M, Muti P, Freudenheim J, Carosella AM, Armstrong D. Correlates of markers of oxidative status in the general population. Am J Epidemiol 154: 348-356, 2001.
47. White C, Liu C, Garcia A, Hamilton E, Chia KK, Figtree GA, Rasmussen HH. Activation of cAMP-dependent signaling induces oxidative modification of the cardiac Na+-K+ pump and inhibits its activity. J Biol Chem 285: 13712-13720, 2010.
48. White CN, Figtree GA, Liu CC, Garcia A, Hamilton EJ, Chia KK, Rasmussen HH. Angiotensin II inhibits the Na+-K+ pump via PKC dependent activation of NADPH oxidase. Am J Physiol Cell Physiol 296: C693-C700, 2009.
49. White CN, Hamilton EJ, Garcia A, Wang D, Chia KK, Figtree GA, Rasmussen HH. Opposing effects of coupled and uncoupled NOS activity on the Na+-K+ pump in cardiac myocytes. Am J Physiol Cell Physiol 294: C572-C578, 2008.
50. William M, Hamilton EJ, Garcia A, Bundgaard H, Figtree GA, Rasmussen HH. Natriuretic peptides stimulate the cardiac sodium pump via NPR-C coupled NOS activation. Am J Physiol Cell Physiol 294: C1067-C1073, 2008.
51. Zielonka J, Vasquez-Vivar J, Kalyanaraman B. Detection of 2-hydroxyethidium in cellular systems: a unique marker product of superoxide and hydroethidine. Nat Protoc 3: 8-21, 2008.
52. Zimmet JM, Hare JM. Nitroso-redox interactions in the cardiovascular system. Circulation 114: 1531-1544, 2006.
53. Zweier JL, Chen CA, Druhan LJ. S-glutathionylation reshapes our understanding of endothelial nitric oxide synthase uncoupling and nitric oxide/reactive oxygen species-mediated signaling. Antioxid Redox Signal 14: 1769-1775, 2011.